1 Report Business Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 1.2.2 Aloxi (Palonosetron) 1.2.3 Kytril (Granisetron) 1.2.4 Emend (Aprepitant) 1.2.5 Others 1.3 Market by Application 1.3.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 1.3.2 Acute Nausea and Vomitting Treatment 1.3.3 Delayed Nausea and Vomitting Treatment 1.3.4 Anticipatory Nausea and Vomitting Treatment 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Perspective (2017-2028) 2.2 Chemotheraphy-induced Nausea and Vomitting Treatment Growth Trends by Region 2.2.1 Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Region (2017-2022) 2.2.3 Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Region (2023-2028) 2.3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Dynamics 2.3.1 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Trends 2.3.2 Chemotheraphy-induced Nausea and Vomitting Treatment Market Drivers 2.3.3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Challenges 2.3.4 Chemotheraphy-induced Nausea and Vomitting Treatment Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Players by Revenue 3.1.1 Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Players by Revenue (2017-2022) 3.1.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Players (2017-2022) 3.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue 3.4 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Concentration Ratio 3.4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue in 2021 3.5 Chemotheraphy-induced Nausea and Vomitting Treatment Key Players Head office and Area Served 3.6 Key Players Chemotheraphy-induced Nausea and Vomitting Treatment Product Solution and Service 3.7 Date of Enter into Chemotheraphy-induced Nausea and Vomitting Treatment Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Chemotheraphy-induced Nausea and Vomitting Treatment Breakdown Data by Type 4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Type (2017-2022) 4.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Type (2023-2028) 5 Chemotheraphy-induced Nausea and Vomitting Treatment Breakdown Data by Application 5.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Application (2017-2022) 5.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2017-2028) 6.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type 6.2.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2017-2022) 6.2.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2023-2028) 6.2.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2017-2028) 6.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application 6.3.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2017-2022) 6.3.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2023-2028) 6.3.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2017-2028) 6.4 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country 6.4.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2017-2022) 6.4.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2023-2028) 6.4.3 United States 6.4.4 Canada 7 Europe 7.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2017-2028) 7.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type 7.2.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2017-2022) 7.2.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2023-2028) 7.2.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2017-2028) 7.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application 7.3.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2017-2022) 7.3.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2023-2028) 7.3.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2017-2028) 7.4 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country 7.4.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2017-2022) 7.4.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2023-2028) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2017-2028) 8.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type 8.2.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2017-2022) 8.2.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2023-2028) 8.2.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2017-2028) 8.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application 8.3.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2017-2022) 8.3.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2023-2028) 8.3.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2017-2028) 8.4 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region 8.4.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2017-2022) 8.4.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2023-2028) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2017-2028) 9.2 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type 9.2.1 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2017-2022) 9.2.2 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2023-2028) 9.2.3 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2017-2028) 9.3 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application 9.3.1 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2017-2022) 9.3.2 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2023-2028) 9.3.3 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2017-2028) 9.4 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country 9.4.1 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2017-2022) 9.4.2 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2023-2028) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2017-2028) 10.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type 10.2.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2017-2022) 10.2.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2023-2028) 10.2.3 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2017-2028) 10.3 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application 10.3.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2017-2022) 10.3.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2023-2028) 10.3.3 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2017-2028) 10.4 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country 10.4.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2017-2022) 10.4.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2023-2028) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 GlaxoSmithKline 11.1.1 GlaxoSmithKline Company Details 11.1.2 GlaxoSmithKline Business Overview 11.1.3 GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Introduction 11.1.4 GlaxoSmithKline Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) 11.1.5 GlaxoSmithKline Recent Developments 11.2 Helsinn 11.2.1 Helsinn Company Details 11.2.2 Helsinn Business Overview 11.2.3 Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Introduction 11.2.4 Helsinn Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) 11.2.5 Helsinn Recent Developments 11.3 Heron Therapeutics 11.3.1 Heron Therapeutics Company Details 11.3.2 Heron Therapeutics Business Overview 11.3.3 Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Introduction 11.3.4 Heron Therapeutics Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) 11.3.5 Heron Therapeutics Recent Developments 11.4 Merck & Co 11.4.1 Merck & Co Company Details 11.4.2 Merck & Co Business Overview 11.4.3 Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Introduction 11.4.4 Merck & Co Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) 11.4.5 Merck & Co Recent Developments 11.5 Tesaro 11.5.1 Tesaro Company Details 11.5.2 Tesaro Business Overview 11.5.3 Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Introduction 11.5.4 Tesaro Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) 11.5.5 Tesaro Recent Developments 11.6 Acacia Pharma 11.6.1 Acacia Pharma Company Details 11.6.2 Acacia Pharma Business Overview 11.6.3 Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Introduction 11.6.4 Acacia Pharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) 11.6.5 Acacia Pharma Recent Developments 11.7 Aphios 11.7.1 Aphios Company Details 11.7.2 Aphios Business Overview 11.7.3 Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Introduction 11.7.4 Aphios Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) 11.7.5 Aphios Recent Developments 11.8 Barr Laboratories 11.8.1 Barr Laboratories Company Details 11.8.2 Barr Laboratories Business Overview 11.8.3 Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Introduction 11.8.4 Barr Laboratories Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) 11.8.5 Barr Laboratories Recent Developments 11.9 Baxter Healthcare 11.9.1 Baxter Healthcare Company Details 11.9.2 Baxter Healthcare Business Overview 11.9.3 Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Introduction 11.9.4 Baxter Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) 11.9.5 Baxter Healthcare Recent Developments 11.10 Eisai 11.10.1 Eisai Company Details 11.10.2 Eisai Business Overview 11.10.3 Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Introduction 11.10.4 Eisai Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) 11.10.5 Eisai Recent Developments 11.11 Especificos Stendhal 11.11.1 Especificos Stendhal Company Details 11.11.2 Especificos Stendhal Business Overview 11.11.3 Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Introduction 11.11.4 Especificos Stendhal Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) 11.11.5 Especificos Stendhal Recent Developments 11.12 F.Hoffmann La Roche 11.12.1 F.Hoffmann La Roche Company Details 11.12.2 F.Hoffmann La Roche Business Overview 11.12.3 F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Introduction 11.12.4 F.Hoffmann La Roche Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) 11.12.5 F.Hoffmann La Roche Recent Developments 11.13 Mundipharma 11.13.1 Mundipharma Company Details 11.13.2 Mundipharma Business Overview 11.13.3 Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Introduction 11.13.4 Mundipharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) 11.13.5 Mundipharma Recent Developments 11.14 Mylan Pharmaceuticals 11.14.1 Mylan Pharmaceuticals Company Details 11.14.2 Mylan Pharmaceuticals Business Overview 11.14.3 Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Introduction 11.14.4 Mylan Pharmaceuticals Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) 11.14.5 Mylan Pharmaceuticals Recent Developments 11.15 OPKO Health 11.15.1 OPKO Health Company Details 11.15.2 OPKO Health Business Overview 11.15.3 OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Introduction 11.15.4 OPKO Health Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) 11.15.5 OPKO Health Recent Developments 11.16 Orchid Healthcare 11.16.1 Orchid Healthcare Company Details 11.16.2 Orchid Healthcare Business Overview 11.16.3 Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Introduction 11.16.4 Orchid Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) 11.16.5 Orchid Healthcare Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Author Details 13.3 Disclaimer

List of Tables Table 1. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028 Table 2. Key Players of Aloxi (Palonosetron) Table 3. Key Players of Kytril (Granisetron) Table 4. Key Players of Emend (Aprepitant) Table 5. Key Players of Others Table 6. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028 Table 7. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 8. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2017-2022) & (US$ Million) Table 9. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Region (2017-2022) Table 10. Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 11. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Region (2023-2028) Table 12. Chemotheraphy-induced Nausea and Vomitting Treatment Market Trends Table 13. Chemotheraphy-induced Nausea and Vomitting Treatment Market Drivers Table 14. Chemotheraphy-induced Nausea and Vomitting Treatment Market Challenges Table 15. Chemotheraphy-induced Nausea and Vomitting Treatment Market Restraints Table 16. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue by Players (2017-2022) & (US$ Million) Table 17. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Share by Players (2017-2022) Table 18. Global Top Chemotheraphy-induced Nausea and Vomitting Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment as of 2021) Table 19. Ranking of Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Companies by Revenue (US$ Million) in 2021 Table 20. Global 5 Largest Players Market Share by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (CR5 and HHI) & (2017-2022) Table 21. Key Players Headquarters and Area Served Table 22. Key Players Chemotheraphy-induced Nausea and Vomitting Treatment Product Solution and Service Table 23. Date of Enter into Chemotheraphy-induced Nausea and Vomitting Treatment Market Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2017-2022) & (US$ Million) Table 26. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Type (2017-2022) Table 27. Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 28. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Type (2023-2028) Table 29. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2017-2022) & (US$ Million) Table 30. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Share by Application (2017-2022) Table 31. Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 32. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Share by Application (2023-2028) Table 33. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2017-2022) & (US$ Million) Table 34. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2023-2028) & (US$ Million) Table 35. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2017-2022) & (US$ Million) Table 36. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2023-2028) & (US$ Million) Table 37. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2017-2022) & (US$ Million) Table 38. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2023-2028) & (US$ Million) Table 39. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2017-2022) & (US$ Million) Table 40. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2023-2028) & (US$ Million) Table 41. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2017-2022) & (US$ Million) Table 42. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2023-2028) & (US$ Million) Table 43. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2017-2022) & (US$ Million) Table 44. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2023-2028) & (US$ Million) Table 45. Asia Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2017-2022) & (US$ Million) Table 46. Asia Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2023-2028) & (US$ Million) Table 47. Asia Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2017-2022) & (US$ Million) Table 48. Asia Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2023-2028) & (US$ Million) Table 49. Asia Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2017-2022) & (US$ Million) Table 50. Asia Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2023-2028) & (US$ Million) Table 51. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2017-2022) & (US$ Million) Table 52. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2023-2028) & (US$ Million) Table 53. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2017-2022) & (US$ Million) Table 54. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2023-2028) & (US$ Million) Table 55. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2017-2022) & (US$ Million) Table 56. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2023-2028) & (US$ Million) Table 57. Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2017-2022) & (US$ Million) Table 58. Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2023-2028) & (US$ Million) Table 59. Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2017-2022) & (US$ Million) Table 60. Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2023-2028) & (US$ Million) Table 61. Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2017-2022) & (US$ Million) Table 62. Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2023-2028) & (US$ Million) Table 63. GlaxoSmithKline Company Details Table 64. GlaxoSmithKline Business Overview Table 65. GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Product Table 66. GlaxoSmithKline Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) & (US$ Million) Table 67. GlaxoSmithKline Recent Developments Table 68. Helsinn Company Details Table 69. Helsinn Business Overview Table 70. Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Product Table 71. Helsinn Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) & (US$ Million) Table 72. Helsinn Recent Developments Table 73. Heron Therapeutics Company Details Table 74. Heron Therapeutics Business Overview Table 75. Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Product Table 76. Heron Therapeutics Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) & (US$ Million) Table 77. Heron Therapeutics Recent Developments Table 78. Merck & Co Company Details Table 79. Merck & Co Business Overview Table 80. Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Product Table 81. Merck & Co Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) & (US$ Million) Table 82. Merck & Co Recent Developments Table 83. Tesaro Company Details Table 84. Tesaro Business Overview Table 85. Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Product Table 86. Tesaro Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) & (US$ Million) Table 87. Tesaro Recent Developments Table 88. Acacia Pharma Company Details Table 89. Acacia Pharma Business Overview Table 90. Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Product Table 91. Acacia Pharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) & (US$ Million) Table 92. Acacia Pharma Recent Developments Table 93. Aphios Company Details Table 94. Aphios Business Overview Table 95. Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Product Table 96. Aphios Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) & (US$ Million) Table 97. Aphios Recent Developments Table 98. Barr Laboratories Company Details Table 99. Barr Laboratories Business Overview Table 100. Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Product Table 101. Barr Laboratories Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) & (US$ Million) Table 102. Barr Laboratories Recent Developments Table 103. Baxter Healthcare Company Details Table 104. Baxter Healthcare Business Overview Table 105. Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product Table 106. Baxter Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) & (US$ Million) Table 107. Baxter Healthcare Recent Developments Table 108. Eisai Company Details Table 109. Eisai Business Overview Table 110. Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Product Table 111. Eisai Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) & (US$ Million) Table 112. Eisai Recent Developments Table 113. Especificos Stendhal Company Details Table 114. Especificos Stendhal Business Overview Table 115. Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Product Table 116. Especificos Stendhal Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) & (US$ Million) Table 117. Especificos Stendhal Recent Developments Table 118. F.Hoffmann La Roche Company Details Table 119. F.Hoffmann La Roche Business Overview Table 120. F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Product Table 121. F.Hoffmann La Roche Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) & (US$ Million) Table 122. F.Hoffmann La Roche Recent Developments Table 123. Mundipharma Company Details Table 124. Mundipharma Business Overview Table 125. Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Product Table 126. Mundipharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) & (US$ Million) Table 127. Mundipharma Recent Developments Table 128. Mylan Pharmaceuticals Company Details Table 129. Mylan Pharmaceuticals Business Overview Table 130. Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Product Table 131. Mylan Pharmaceuticals Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) & (US$ Million) Table 132. Mylan Pharmaceuticals Recent Developments Table 133. OPKO Health Company Details Table 134. OPKO Health Business Overview Table 135. OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Product Table 136. OPKO Health Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) & (US$ Million) Table 137. OPKO Health Recent Developments Table 138. Orchid Healthcare Company Details Table 139. Orchid Healthcare Business Overview Table 140. Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product Table 141. Orchid Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) & (US$ Million) Table 142. Orchid Healthcare Recent Developments Table 143. Research Programs/Design for This Report Table 144. Key Data Information from Secondary Sources Table 145. Key Data Information from Primary Sources List of Figures Figure 1. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type: 2021 VS 2028 Figure 2. Aloxi (Palonosetron) Features Figure 3. Kytril (Granisetron) Features Figure 4. Emend (Aprepitant) Features Figure 5. Others Features Figure 6. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application: 2021 VS 2028 Figure 7. Acute Nausea and Vomitting Treatment Case Studies Figure 8. Delayed Nausea and Vomitting Treatment Case Studies Figure 9. Anticipatory Nausea and Vomitting Treatment Case Studies Figure 10. Chemotheraphy-induced Nausea and Vomitting Treatment Report Years Considered Figure 11. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 12. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 13. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Region: 2021 VS 2028 Figure 14. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Players in 2021 Figure 15. Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment as of 2021) Figure 16. The Top 10 and 5 Players Market Share by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue in 2021 Figure 17. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY (2017-2028) & (US$ Million) Figure 18. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Market Share by Type (2017-2028) Figure 19. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Market Share by Application (2017-2028) Figure 20. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Country (2017-2028) Figure 21. United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 22. Canada Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 23. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY (2017-2028) & (US$ Million) Figure 24. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Market Share by Type (2017-2028) Figure 25. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Market Share by Application (2017-2028) Figure 26. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Country (2017-2028) Figure 27. Germany Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. France Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. U.K. Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Italy Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Russia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. Nordic Countries Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY (2017-2028) & (US$ Million) Figure 34. Asia Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Market Share by Type (2017-2028) Figure 35. Asia Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Market Share by Application (2017-2028) Figure 36. Asia Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Region (2017-2028) Figure 37. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. Japan Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. South Korea Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 40. Southeast Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. India Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 42. Australia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2017-2028) & (US$ Million) List of Figures Figure 43. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY (2017-2028) & (US$ Million) Figure 44. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Market Share by Type (2017-2028) Figure 45. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Market Share by Application (2017-2028) Figure 46. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Country (2017-2028) Figure 47. Mexico Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 48. Brazil Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 49. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY (2017-2028) & (US$ Million) Figure 50. Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Market Share by Type (2017-2028) Figure 51. Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Market Share by Application (2017-2028) Figure 52. Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Country (2017-2028) Figure 53. Turkey Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 54. Saudi Arabia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 55. UAE Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 56. GlaxoSmithKline Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) Figure 57. Helsinn Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) Figure 58. Heron Therapeutics Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) Figure 59. Merck & Co Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) Figure 60. Tesaro Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) Figure 61. Acacia Pharma Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) Figure 62. Aphios Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) Figure 63. Barr Laboratories Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) Figure 64. Baxter Healthcare Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) Figure 65. Eisai Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) Figure 66. Especificos Stendhal Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) Figure 67. F.Hoffmann La Roche Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) Figure 68. Mundipharma Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) Figure 69. Mylan Pharmaceuticals Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) Figure 70. OPKO Health Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) Figure 71. Orchid Healthcare Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022) Figure 72. Bottom-up and Top-down Approaches for This Report Figure 73. Data Triangulation Figure 74. Key Executives Interviewed

GlaxoSmithKline Helsinn Heron Therapeutics Merck & Co Tesaro Acacia Pharma Aphios Barr Laboratories Baxter Healthcare Eisai Especificos Stendhal F.Hoffmann La Roche Mundipharma Mylan Pharmaceuticals OPKO Health Orchid Healthcare